CYP2A6 - cytochrome P450 family 2 subfamily A member 6 Gene

Also Known as CPA6; CYP2A; CYP2A3; P450PB; CYPIIA6; P450C2A

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 1548

About CYP2A6

Cytogenetic location: 19q13.2 Genomic coordinates (GRCh38): 19:40,843,541-40,850,447 (from NCBI)

This gene has 4 transcripts (splice variants), 117 orthologues, 15 paralogues and is associated with 5 phenotypes. Restricted expression toward liver (RPKM 542.0).

Summary

This gene, CYP2A6, encodes a member of the Cytochrome P450 superfamily of Enzymes. The Cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of Cholesterol, Steroids and Other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of Cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq, Jul 2008]

CYP2A6 Products (1)

mRNA Protein Name
NM_000762.6 NP_000753.3 cytochrome P450 2A6 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables coumarin 7-hydroxylase activity IDA
IDA: Inferred from direct assay
16086027 GOA
enables enzyme binding IPI
IPI: Inferred from physical interaction
15680923 GOA
enables heme binding IDA
IDA: Inferred from direct assay
16086027 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
28514442 GOA
Biological Process GO Annotation Evidence References Source
involved in coumarin catabolic process IDA
IDA: Inferred from direct assay
19029318 GOA
involved in coumarin metabolic process IDA
IDA: Inferred from direct assay
19651758 GOA
involved in steroid metabolic process IMP
IMP: Inferred from mutant phenotype
18356043 GOA
involved in xenobiotic catabolic process IDA
IDA: Inferred from direct assay
15680923 GOA
involved in xenobiotic metabolic process IDA
IDA: Inferred from direct assay
19651758 GOA
involved in xenobiotic metabolic process IMP
IMP: Inferred from mutant phenotype
18356043 GOA
Cellular Component GO Annotation Evidence References Source
located in cytoplasmic microtubule IDA
IDA: Inferred from direct assay
23264731 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

CYP2A6 Protein Structure

p450

p450: Cytochrome P450 (34 - 490)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 494 a.a.
Protein Preferred Names Protein Names

cytochrome P450 2A6

  • 1,4-cineole 2-exo-monooxygenase

CYP2A6 Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method References
Intra
CYP2A6 P11509 RABAC1 Homo sapiens Q9UI14
Anti Tag CoIP
33961781
Intra
CYP2A6 P11509 RABAC1 Homo sapiens Q9UI14
Anti Tag CoIP
28514442
Cross: Cross-species interaction Intra: Intraspecies interaction

Related Diseases

Diseases Alias
Tobacco Addiction

  • Nicotine Dependence

  • Tobacco Addiction, Susceptibility To

  • Nicotine Addiction

  • Tobacco Use Disorder

  • Smoking Habit

  • Nicotine Dependence, Protection Against

  • Nicotine Addiction, Protection From

  • Cigarette Habituation

  • Cigarette Habituation, Susceptibility To

  • Smoking Habit, Susceptibility To

  • Nicotine Dependence, Susceptibility To

  • Nicotine Addiction, Susceptibility To

  • Addiction, Tobacco, Susceptibility To

  • Compulsive Tobacco User Syndrome

  • Tobacco Dependence

  • Tobacco Dependence Syndrome

  • Cigarette Addiction

  • Cigarette Dependence

  • Smoking Addiction

  • Smokers Syndrome
Coumarin Resistance

  • Warfarin Resistance

  • Warfarin Sensitivity

  • Coumadin Sensitivity

  • Warfarin Response

  • Poor Metabolism Of Coumarin

  • Coumarin, Poor Metabolism Of

  • CMRES
Lung Cancer

  • Lung Carcinoma

  • Non-Small Cell Lung Carcinoma

  • Lung Cancer, Susceptibility To

  • Lung Cancer, Protection Against

  • Adenocarcinoma Of Lung, Somatic

  • Adenocarcinoma Of Lung, Response To Tyrosine Kinase Inhibitor In

  • Nonsmall Cell Lung Cancer

  • Lung Neoplasm

  • Carcinoma Of Lung

  • Lung Non-Small Cell Carcinoma

  • Non-Small Cell Lung Cancer

  • Nsclc

  • Lung Neoplasms

  • Malignant Neoplasm Of Lung

  • Alveolar Cell Carcinoma

  • Nonsmall Cell Lung Cancer, Somatic

  • Nonsmall Cell Lung Cancer, Response To Tyrosine Kinase Inhibitor In

  • Nonsmall Cell Lung Cancer, Susceptibility To

  • Lung Cancer, Somatic

  • Lung Cancer, Resistance To

  • Cancer Of Lung

  • Cancer Of Bronchus

  • Cancer Of The Lung

  • Lung Malignancies

  • Lung Malignant Tumors

  • Malignant Lung Tumor

  • Malignant Tumor Of Lung

  • Pulmonary Cancer

  • Pulmonary Carcinoma

  • Pulmonary Neoplasms

  • Respiratory Carcinoma

  • LNCR

  • Adenocarcinoma Of Lung

  • Neoplasm Of Lung

  • Cancer Lung

  • Carcinoma Non-Small Cell Lung

  • Carcinoma, Non-Small-Cell Lung

  • Lung Cancers

  • Lung Carcinomas

  • Cancer, Lung

  • Cancer, Lung, Non-Small Cell

  • Primary Malignant Neoplasm Of Lung

  • Bronchioloalveolar Adenocarcinoma
Letrozole Toxicity
Acetaminophen Metabolism
Liver Cirrhosis

  • Cirrhosis

  • Cirrhosis Of Liver

  • CIRRH

  • Cryptogenic Cirrhosis

  • Cirrhosis, Cryptogenic

  • Cirrhosis Nos
Substance Dependence
Alcoholic Liver Cirrhosis

  • Alcoholic Cirrhosis

  • Portal Cirrhosis

  • Alcoholic Cirrhosis Of Liver

  • Liver Cirrhosis, Alcoholic

  • Laennec'S Cirrhosis

  • Laennec'S Cirrhosis, Alcoholic

  • Alcohol Cirrhosis

  • Alcoholic Laennec Cirrhosis

  • Alcoholic Cirrhosis Nos

  • Etoh Cirrhosis

  • Alcohol Hepatic Cirrhosis

  • Alcohol Liver Cirrhosis

  • Laennec Cirrhosis
Tinea Cruris

  • Dermatophytosis Of Groin & Perianal Area

  • Dermatophytosis Of Groin And Perianal Area

  • Dhobie Itch

  • Tinea Of Perianal Region
Lung Adenoma

  • Adenoma Of Lung

  • Pulmonary Adenoma
Colorectal Cancer

  • Colon Cancer

  • Colorectal Carcinoma

  • Colon Carcinoma

  • Colorectal Cancer, Susceptibility To

  • Carcinoma Of Colon

  • CRC

  • Colorectal Cancer With Chromosomal Instability, Somatic

  • Colon Cancer, Somatic

  • Colon Cancer, Susceptibility To

  • Colonic Neoplasms

  • Colorectal Neoplasms

  • Colorectal Cancer, Somatic

  • Colon Cancer, Advanced, Somatic

  • Colonic Carcinoma

  • Colorectal Carcinomas

  • Colon Cancers

  • Colorectal Cancers

  • Cancer, Colorectal, Somatic

  • Cancer, Colon

  • Cancer, Colorectal, Susceptibility To

  • Colorectal Neoplasm

  • Colonic Neoplasm

  • Malignant Tumor Of Colon
Bilirubin Metabolic Disorder

  • Hyperbilirubinemia

  • Hereditary Hyperbilirubinemia

  • Hyperbilirubinemia, Hereditary

  • Hyperbilirubinaemia
Body Mass Index Quantitative Trait Locus 11

  • OBESITY

  • Obesity, Susceptibility To

  • Leanness, Inherited

  • Obesity, Susceptibility To, Bmiq11

  • Obesity, Mild, Early-Onset

  • Obesity, Association With

  • Obesity, Early-Onset, Susceptibility To

  • Obesity, Severe

  • Obesity, Severe, And Type Ii Diabetes

  • Obesity, Late-Onset

  • Obesity , Susceptibility To

  • BMIQ11

  • Obesity Bmiq11

  • Obesity, Early-Onset

  • Simple Obesity Nos

  • Excess Fat

  • Obesity, Not Elsewhere Classified, Body Mass Index Not Elsewhere Classified

  • Adiposis
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-17356 Fenofibrate 99.97% Yes
HY-122272 Paroxetine 99.66% Yes
HY-B0492 Paroxetine hydrochloride 99.98% Unkown
HY-17459 Clopidogrel hydrogen sulfate Inhibitor 99.88% Yes
HY-B1184 Mephenytoin 99.96% Unkown
HY-B1694A Methoxyphenamine hydrochloride ≥98.0% Unkown
HY-B2169 Melperone 99.84% Yes
HY-122272R Paroxetine (Standard) 99.79% Unkown
HY-17459R Clopidogrel hydrogen sulfate (Standard) Inhibitor / Unkown
HY-B0773 Paroxetine mesylate / Unkown

Clinical Phase

Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Phase
HY-129105 Clomethiazole 99.35% Phase 3
HY-A0296 Chlormethiazole hydrochloride Inhibitor 99.94% Phase 3
HY-W344044 Levomepromazine maleate 99.92% Phase 3
HY-103109 Melperone hydrochloride / Phase 3
HY-116780 Prothipendyl Substrate / Phase 3
HY-15163 Zotiraciclib Inhibitor 99.88% Phase 2
HY-19397 BMS-223131 / Phase 2
HY-12946 BI 653048 Inhibitor 99.84% Phase 1
HY-12946A BI 653048 phosphate Inhibitor / Phase 1
HY-19379 E-2101 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (120)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-N0904 Ginsenoside C-K Inhibitor 99.93% Unkown
HY-N0494 Gentiopicroside Inhibitor 99.83% Unkown
HY-N0043 Ginsenoside Rd Inhibitor 99.88% Unkown
HY-105124 Bufuralol Antagonist 99.25% Unkown
HY-W008364 Olivetol Inhibitor 99.84% Unkown
HY-W013268 (S)-(+)-N-3-Benzylnirvanol Inhibitor 99.76% Unkown
HY-105124A Bufuralol hydrochloride Antagonist ≥99.0% Unkown
HY-100637 Hydroxybupropion 99.91% Unkown
HY-N0762 Isobavachin 99.88% Unkown
HY-18063 ML252 Inhibitor 99.9% Unkown
HY-N2260 Cephaeline dihydrochloride Inhibitor 99.67% Unkown
HY-135560 Nicotelline Inhibitor 98.88% Unkown
HY-N5092 7-Methylcoumarin 99.93% Unkown
HY-N4322 Decursinol angelate Activator 99.94% Unkown
HY-N0241 Rhodionin Inhibitor 99.73% Unkown
HY-N0598 Ginsenoside F1 Inhibitor 99.86% Unkown
HY-W040468 2-Phenyl-2-(1-piperidinyl)propane Inhibitor 99.72% Unkown
HY-N1050 Zederone Inhibitor 99.61% Unkown
HY-N2382 Polyphyllin H Inhibitor 99.89% Unkown
HY-N2425 Rhodiosin Inhibitor 99.07% Unkown
HY-14362 GSK-25 Inhibitor 98.33% Unkown
HY-151239 ONT-993 Inhibitor 99.85% Unkown
HY-16718 Dagrocorat 99.90% Unkown
HY-17356R Fenofibrate (Standard) 99.92% Unkown
HY-N2129 N-Nornuciferine Inhibitor 99.94% Unkown
HY-W010195 2,6-Dimethylquinoline Inhibitor 99.95% Unkown
HY-W587878 Thujopsene 86.31% Unkown
HY-100238 Antihistamine-1 Inhibitor 99.08% Unkown
HY-116780A Prothipendyl hydrochloride Substrate 99.94% Unkown
HY-17356S Fenofibrate-d6 99.70% Unkown
HY-N5132 (-)-Fenchone 98.0% Unkown
HY-12767 Carvedilol metabolite 4-Hydroxyphenyl Carvedilol 98.59% Unkown
HY-133116 4-Hydroxyatomoxetine 97.04% Unkown
HY-N8382 Chalepensin Inhibitor 98.98% Unkown
HY-W754151 N-Desmethyl apalutamide-d4 99.63% Unkown
HY-100064 O-Desmethyl gefitinib Inhibitor 99.40% Unkown
HY-133116S 4-Hydroxyatomoxetine-d3 98.89% Unkown
HY-135810 Cletoquine Inhibitor / Unkown
HY-135810A Cletoquine oxalate Inhibitor 99.63% Unkown
HY-16718A Dagrocorat hydrochloride 99.85% Unkown
HY-170928 DA-0157 Inhibitor 99.59% Unkown
HY-20313 3-Methylbenzofuran Inhibitor 99.28% Unkown
HY-B0352A (S)-Mirtazapine Antagonist 99.76% Unkown
HY-B0365AS Memantine-d6 hydrochloride 99.83% Unkown
HY-B1184S1 Mephenytoin-d5 98.72% Unkown
HY-N1483 Guanfu base A Inhibitor 98.10% Unkown
HY-131630 O-Desmethylmetoprolol 98.66% Unkown
HY-132428S O-Desmethyl Tramadol-d6 / Unkown
HY-18063A ML252 hydrochloride Inhibitor 98.5% Unkown
HY-N6023 Thermopsoside 98.0% Unkown
HY-W067374 Aripiprazole impurity 38 97.79% Unkown
HY-W082430 CYP2A6-IN-2 Inhibitor 97.61% Unkown
HY-W740630 8-Hydroxy mirtazapine Control 99.95% Unkown
HY-170569 Cetagliptin / Unkown
HY-100064S O-Desmethyl gefitinib-d8 Inhibitor 99.84% Unkown
HY-100064S1 O-Desmethyl gefitinib-d6 Inhibitor / Unkown
HY-10572A (R)-Efavirenz Inhibitor / Unkown
HY-10575 MK-5596 / Unkown
HY-10672 Urotensin-II receptor antagonist-1 / Unkown
HY-110134 S07662 Inhibitor / Unkown
HY-111124 Paroxetine-d2 / Unkown
HY-112142A (Rac)-AB-423 Inhibitor / Unkown
HY-113575 Dehydroaripiprazole hydrochloride Agonist / Unkown
HY-117593 NSC 23925B Inhibitor / Unkown
HY-117599 JPC-3210 Inhibitor / Unkown
HY-122272S2 Paroxetine-d6-1 / Unkown
HY-134522 DL5050 Agonist / Unkown
HY-134664 8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate Inhibitor / Unkown
HY-135810S Cletoquine-d4 Inhibitor / Unkown
HY-135810S1 Cletoquine-d4-1 Inhibitor / Unkown
HY-144285 CXCR4 antagonist 4 Antagonist / Unkown
HY-144286 CXCR4 antagonist 3 Inhibitor / Unkown
HY-146177 CYP3A4 enzyme-IN-1 Inhibitor / Unkown
HY-147810 5-HT7 receptor ligand 1 / Unkown
HY-148597 FGFR-IN-10 Inhibitor / Unkown
HY-156330 HIV-IN-9 Inhibitor / Unkown
HY-159143 BChE-IN-33 Inhibitor / Unkown
HY-160828 O-Desmethyl dacomitinib Inhibitor / Unkown
HY-173032 VU6033685 Agonist / Unkown
HY-173465 DL5055 Agonist / Unkown
HY-17356G Fenofibrate (GMP) / Unkown
HY-17356S1 Fenofibrate-d4 / Unkown
HY-17459S Clopidogrel-d3 hydrogen sulfate / Unkown
HY-175064 3,4-Methylenedioxyphenmetrazine hydrochloride Inhibitor / Unkown
HY-178786 RET-IN-31 Inhibitor / Unkown
HY-182735 BMS-570520 / Unkown
HY-B0352AS (S)-Mirtazapine-d3 Antagonist 99.0% Unkown
HY-B1184S2 Mephenytoin-d8 / Unkown
HY-B1184S3 Mephenytoin-13C,d3 / Unkown
HY-N0043R Ginsenoside Rd (Standard) Inhibitor / Unkown
HY-N0904R Ginsenoside C-K (Standard) Inhibitor / Unkown
HY-N11706 β-Cedrene Inhibitor 98.94% Unkown
HY-N1483A Guanfu base A hydrochloride Inhibitor / Unkown
HY-N18161 Isopsoralidin Inhibitor / Unkown
HY-N2129A N-Nornuciferine hydrochloride Inhibitor / Unkown
HY-N3090 Peucedanol Inhibitor / Unkown
HY-N6989 Isoglycycoumarin / Unkown
HY-RS03454 CYP2A6 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS03456 CYP2B6 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS03461 CYP2D6 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W008364S1 Olivetol-d9 / Unkown
HY-W099758 Gamma-heptalactone Inhibitor 99.90% Unkown
HY-W140208 3-Phenylthiophene Inhibitor / Unkown
HY-W663179 DNDI-VL-2098 Inhibitor / Unkown
HY-W777442 Cletoquine-d4 Oxalate Inhibitor / Unkown
HY-100665S Dehydroaripiprazole-d8 Agonist / Unkown
HY-122272A Paroxetine acetate / Unkown
HY-122272S Paroxetine-d4 / Unkown
HY-155456 CYP2A6-IN-1 Inhibitor / Unkown
HY-169119 Antifungal agent 114 Inhibitor / Unkown
HY-17356S2 Fenofibrate-13C6 / Unkown
HY-24238 DLCI-1 Inhibitor / Unkown
HY-76569B 5-Hydroxymethyl tolterodine formate Antagonist / Unkown
HY-B1184S Mephenytoin-d3 99.52% Unkown
HY-B2169S2 Melperone-d4 hydrochloride 99.84% Unkown
HY-W587570 (S)-4-Hydroxymephenytoin / Unkown
HY-W702646 Hydroxymethyl tolperisone hydrochloride Control / Unkown
HY-W803860 N-Depropylpropafenone Antagonist / Unkown
HY-Z2493 Aripiprazole N1-oxide Control / Unkown
HY-Z9101 Promethazine sulfoxide Control / Unkown